Hong Kong Stock Market Update: Innovative Drug Stocks Rise as Multiple Rare Disease Therapies Included in National Reimbursement and Commercial Insurance Formularies

According to the Zhicheng Finance APP, some innovative drug concept stocks rose in the morning session. As of press time, JW Therapeutics-B (02126) surged 8.77% to HK$3.35; CARsgen Therapeutics-B (02171) increased by 3.8% to HK$18.87; CANbridge-B (01228) climbed 3.38% to HK$2.45; Junshi Biosciences (01877) gained 2.29% to HK$24.1.

In terms of news, the 2025 National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalogue marks the 8th adjustment since the establishment of the National Healthcare Security Administration. This catalogue adjustment adds 114 new drugs, 50 of which are Class 1 innovative medicines. According to Cailian Press, Fosun Pharmaceutical's Luvoxametinib tablets have been included in the 2025 medical insurance catalogue, while CANbridge's Velaglucerase Alfa for injection has entered the commercial insurance innovative drug catalogue.

Notably, the much-anticipated million-CAR-T cell therapies – Fosun Kite's Axicabtagene Ciloleucel Injection, JW Therapeutics' Relmacabtagene Autoleucel Injection, Juventas' Naxicabtagene Autoleucel Injection, IASO Bio's Ebcabtagene Autoleucel Injection, and Ascend Biopharmaceuticals' Zevorcabtagene Autoleucel Injection – have all been included in the first batch of commercial insurance innovative drug directory.